Most patients presented with predominant liver disease (54.8%), with 37.0% (n = 23) already at an advanced stage of liver disease compatible with cirrhosis and 26.6% (n = 25) with asymptomatic elevation of liver enzymes alanine transaminase (ALT) and aspartate transaminase (AST); mixed hepatic and neurological manifestations were observed in 17.9% (n = 15) and mainly neurological symptoms in 10.7% (n = 9). This evidence concerns the gene GPT and Cirrhosis.